Chogtu, Bharti and Kalthur, Sneha G (2020) Effect of Vitamin D Analogue on Rosuvastatin-Induced Myopathy in Wistar Rats. The Scientific World Journal, 2020. pp. 1-6. ISSN 1537-744X.

PDF 00008555.PDF - Published Version Restricted to Registered users only Download (2MB) | Request a copy

Abstract

Objectives. Statin-induced myopathy is one of the major causes of poor adherence and discontinuation of this medication. )ere are contrary results regarding association of vitamin D insufficiency with statin-induced myopathy. )is study was done to determine the effect of the vitamin D3 analogue alfacalcidol on Rosuvastatin-induced myopathy in rats. Methodology. Animals were divided into six groups with 6 rats in each group. Groups I and II acted as controls, Group III and Group IV were administered Rosuvastatin 120 mg/kg/day and 160 mg/kg/day, Groups V and VI were administered alfacalcidol 0.1 μg/kg/day in addition to Rosuvastatin 120 mg/kg/day and 160 mg/kg/day, respectively. All drugs were administered orally for 15 days. Plasma creatine kinase (CK) levels were estimated on day 10 and day 15. Animals were sacrificed and muscles were sent for histo�pathological examination. Results. On day 10, Groups V and VI showed a statistically significant increase in plasma CK levels as compared to the control (p < 0.001) and were significantly lower (p < 0.001) as compared to Groups III and IV, respectively. However, on day 15, plasma CK levels in Groups V and VI were comparable to those of control groups with a nonsignificant difference (p > 0.05). On comparing the histology, Groups V and VI showedasignificantdifferenceascomparedtostatin-only groups (Groups III and IV) as there were signs of regeneration, less splitting, and fragmentation of muscle fibres. Conclusion. ) present study shows that the vitamin D analogue alfacalcidol prevents statin-induced myopathy. )e serum CK levels arecomparable to the control group on day 15 of vitamin D administration.

Actions (login required)

View Item